Results 61 to 70 of about 1,848 (184)

Selexipag for pulmonary arterial hypertension in a wide range of adult congenital heart disease

International Journal of Cardiology Congenital Heart Disease, 2021
Background: Selexipag has been recognised as effective treatment for pulmonary arterial hypertension (PAH). However, evidence for its use in PAH associated with congenital heart disease (CHD) is limited to those with PAH after simple defect correction ...
Alexandra C. van Dissel, Marco C. Post, GertJan T. Sieswerda, Hubert W. Vliegen, Arie P.J. van Dijk, Barbara J.M. Mulder, Berto J. Bouma   +6 more
doaj   +1 more source

Evidence for PDZ‐Binding Kinase in Lung Disease With an Emphasis on PAH

Pulmonary Circulation, Volume 16, Issue 3, July 2026.
ABSTRACT Originally named T‐cell‐originated Lymphokine‐activated killer protein kinase (TOPK), PDZ‐Binding Kinase (PBK) is a serine/threonine kinase that is a member of the family of mitogen‐activated protein kinases (MAPKKs), which is overexpressed in lung cancer and interstitial pulmonary fibrosis (IPF). Along these lines, recent work also shows that
Scott A. Barman, Zsuzsanna Bordan, David J. R. Fulton   +2 more
wiley   +1 more source

Population pharmacokinetics of selexipag for dose selection and confirmation in pediatric patients with pulmonary arterial hypertension

CPT: Pharmacometrics & Systems Pharmacology
Selexipag is an oral selective prostacyclin receptor agonist approved for the treatment of pulmonary arterial hypertension (PAH) in adults. To date, no treatment targeting the prostacyclin pathway is approved for pediatric patients.
Lene Nygaard Axelsen, Anne Kümmel, Juan Jose Perez Ruixo, Alberto Russu   +3 more
doaj   +1 more source

Effectiveness of PAH Specific Treatment Is Comparable Between PAH Associated With Connective Tissue Disease and Idiopathic PAH: Data From the Multicentre National Registry

Pulmonary Circulation, Volume 16, Issue 3, July 2026.
ABSTRACT Pulmonary arterial hypertension (PAH) is a rare disease with poor prognosis. The same treatment is recommended in patients with PAH associated with connective tissue disease (CTD) and idiopathic PAH (IPAH). However, the effectiveness of PAH‐specific treatment in these both groups is inconsistent.
Anna Smukowska‐Gorynia, Sylwia Iwańczyk, Michał Ciurzyński, Marcin Waligóra, Marcin Kurzyna, Piotr Pruszczyk, Grzegorz Kopeć, Katarzyna Mizia‐Stec, Ilona Skoczylas, Łukasz Chrzanowski, Piotr Błaszczak, Katarzyna Ptaszyńska, Grzegorz Grześk, Ewa Malinowska, Małgorzata Peregud‐Pogorzelska, Michał Tomaszewski, Ewa Mroczek, Miłosz Jaguszewski, Ewa Lewicka, Katarzyna Widejko, Agnieszka Pawlak, Wojciech Jacheć, Zbigniew Gąsior, Katarzyna Betkier‐Lipińska, Judyta Winowska‐Józwa, Marta Banaszkiewicz, Tatiana Mularek‐Kubzdela   +26 more
wiley   +1 more source

Determining the value contribution of selexipag for the treatment of pulmonary arterial hypertension (PAH) in Spain using reflective multi-criteria decision analysis (MCDA)

Orphanet Journal of Rare Diseases, 2018
Background Pulmonary Arterial Hypertension (PAH) is a chronic rare disease that can lead to serious cardiovascular problems and death. Additional treatments that increase effectiveness, that are safe and with a convenient administration that improve ...
Alberto Jiménez, Arantza Ais, Amélie Beaudet, Alicia Gil   +3 more
doaj   +1 more source

The Role of Medical Therapy Before and After Balloon Pulmonary Angioplasty: CTEPH AC Registry Across Japan

Pulmonary Circulation, Volume 16, Issue 3, July 2026.
ABSTRACT We aimed to evaluate the role of medical therapy before and after balloon pulmonary angioplasty (BPA) for non‐operable chronic thromboembolic pulmonary hypertension (CTEPH) in the modern management era. This Japanese nationwide, multicenter, prospective observational registry, including 37 centers, analyzed data newly registered from August ...
Miki Sakamoto‐Iwata, Yu Taniguchi, Kohei Masaki, Kazuya Hosokawa, Shiro Adachi, Takumi Inami, Jun Yamashita, Hitoshi Ogino, Masaru Hatano, Ichizo Tsujino, Nobuhiro Yaoita, Nobutaka Ikeda, Hiroto Shimokawahara, Nobuhiro Tanabe, Kayoko Kubota, Ayako Shigeta, Yoshito Ogihara, Koshin Horimoto, Yoshihiro Dohi, Takahiro Hiraide, Takashi Kawakami, Yuichi Tamura, Yoshihiro Fukumoto, Kohtaro Abe   +23 more
wiley   +1 more source

Datasheet1_A Canadian, retrospective, multicenter experience with selexipag for a heterogeneous group of pediatric pulmonary hypertension patients.pdf

, 2023
IntroductionSelexipag, an oral nonprostanoid prostaglandin receptor agonist, has led to reduced morbidity and mortality in adults with pulmonary arterial hypertension (PAH). While the adult literature has been extrapolated to suggest selexipag as an oral
Martin Hosking (4983554), Matthew Pietrosanu (14501648), David Youssef (14686570), Jenna Smith (10896720), Susan Richards (14501642), Catherine Sheppard (4832118), Erika Vorhies (14686576), Angela Bates (4055455), Sabine Lague (14686573)   +8 more
core   +1 more source

Impact of selexipag maintenance dose on persistence, adherence, and hospitalization in US patients with pulmonary arterial hypertension

Pulmonary Circulation
Selexipag is an oral selective agonist of the prostacyclin receptor approved to treat adults with pulmonary arterial hypertension (PAH). Selexipag is initiated at a dose of 200 μg twice daily (bid) and usually titrated up by 200 μg bid weekly (per label)
Charles D. Burger, Wenze Tang, Yuen Tsang, Sumeet Panjabi   +3 more
doaj   +1 more source

Observed Weight Gain in Patients With Pulmonary Arterial Hypertension Treated With Sotatercept

Pulmonary Circulation, Volume 16, Issue 3, July 2026.
ABSTRACT Sotatercept, an activin signaling inhibitor for pulmonary arterial hypertension (PAH), has demonstrated significant improvements in clinical outcomes though its off‐target effects are still an area for discovery. Anecdotal increases in total body weight not attributable to fluid retention have been observed.
Rebecca A. Greene, Darlene Tat, Allyson Sherman‐Roe, Tiffaney Cayton, Jacqueline Lopes, Alexander Jorrin, James Klinger, Christopher J. Mullin, Kathryn Needle, William M. Oldham, Crossandra Osgood, Navneet Singh, Corey E. Ventetuolo   +12 more
wiley   +1 more source

Efficacy and Safety of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis:A Randomized, Placebo-Controlled, Phase II Study [PDF]

, 2017
Objective: To determine the effect of selexipag, an oral, selective IP prostacyclin receptor agonist, on the frequency of attacks of Raynaud's phenomenon (RP) in patients with systemic sclerosis (SSc).
Schwarting, A, Denton, CP, Éric Hachulla, Raynaud Study Investigators, Herrick, AL, Franck-Olivier Le Brun, Gabriela Riemekasten, Frenoux, Jean Marie, Le Brun, Franck Olivier, Le Brun, F-O, Jean-Marie Frenoux, Hachulla, Éric, Aline Frey, Denton, Christopher P., Riemekasten, G, Andreas Schwarting, Christopher P. Denton, Frey, A, Hachulla, É, Frenoux, J-M, null null, Riemekasten, Gabriela, Herrick, Ariane L., Ariane L. Herrick, Frey, Aline, Schwarting, Andreas   +25 more
core   +1 more source